Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.

Kenakin T, Bylund DB, Toews ML, Mullane K, Winquist RJ, Williams M.

Biochem Pharmacol. 2014 Jan 1;87(1):64-77. doi: 10.1016/j.bcp.2013.10.024. Epub 2013 Nov 19. Review.

PMID:
24269285
2.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
3.

Pharmacokinetics and the drug-target residence time concept.

Dahl G, Akerud T.

Drug Discov Today. 2013 Aug;18(15-16):697-707. doi: 10.1016/j.drudis.2013.02.010. Epub 2013 Mar 14. Review.

PMID:
23500610
4.

Evaluation of drug transporter interactions in drug discovery and development.

Lai Y, Sampson KE, Stevens JC.

Comb Chem High Throughput Screen. 2010 Feb;13(2):112-34. Review.

PMID:
20053160
5.

Model-based drug discovery: implementation and impact.

Visser SA, Aurell M, Jones RD, Schuck VJ, Egnell AC, Peters SA, Brynne L, Yates JW, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U.

Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012. Epub 2013 May 29. Review.

PMID:
23726890
6.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
7.

Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.

Clas SD, Sanchez RI, Nofsinger R.

Drug Discov Today. 2014 Jan;19(1):79-87. doi: 10.1016/j.drudis.2013.08.014. Epub 2013 Aug 27. Review.

PMID:
23993918
9.

Ex Vivo Metrics, a preclinical tool in new drug development.

Curtis CG, Bilyard K, Stephenson H.

J Transl Med. 2008 Jan 23;6:5. doi: 10.1186/1479-5876-6-5. Review.

10.

A network view of disease and compound screening.

Schadt EE, Friend SH, Shaywitz DA.

Nat Rev Drug Discov. 2009 Apr;8(4):286-95. doi: 10.1038/nrd2826. Review.

PMID:
19337271
11.

An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.

Sugaya N, Ikeda K, Tashiro T, Takeda S, Otomo J, Ishida Y, Shiratori A, Toyoda A, Noguchi H, Takeda T, Kuhara S, Sakaki Y, Iwayanagi T.

BMC Pharmacol. 2007 Aug 20;7:10.

12.

Requirements for a lead compound to become a clinical candidate.

Hefti FF.

BMC Neurosci. 2008 Dec 10;9 Suppl 3:S7. doi: 10.1186/1471-2202-9-S3-S7. Review.

13.

Target engagement in lead generation.

Durham TB, Blanco MJ.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):998-1008. doi: 10.1016/j.bmcl.2014.12.076. Epub 2015 Jan 12. Review.

14.

Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.

Meanwell NA.

Chem Res Toxicol. 2011 Sep 19;24(9):1420-56. doi: 10.1021/tx200211v. Epub 2011 Jul 26. Review.

PMID:
21790149
15.

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):195-209. doi: 10.1111/j.1742-7843.2009.00513.x. Epub 2009 Dec 29. Review.

16.

De-risking drug discovery with ADDME -- avoiding drug development mistakes early.

Tsaioun K, Jacewicz M.

Altern Lab Anim. 2009 Sep;37 Suppl 1:47-55. Review.

PMID:
19807206
17.

Drug-therapy networks and the prediction of novel drug targets.

Spiro Z, Kovacs IA, Csermely P.

J Biol. 2008 Jul 31;7(6):20. doi: 10.1186/jbiol81. Review.

18.

Solubility and permeability measurement and applications in drug discovery.

Burton PS, Goodwin JT.

Comb Chem High Throughput Screen. 2010 Feb;13(2):101-11. Review.

PMID:
20053165
19.

From fragment to clinical candidate--a historical perspective.

Chessari G, Woodhead AJ.

Drug Discov Today. 2009 Jul;14(13-14):668-75. doi: 10.1016/j.drudis.2009.04.007. Epub 2009 May 7. Review.

PMID:
19427404
20.

[Prediction of network drug target based on improved model of bipartite graph valuation].

Liu X, Lu P, Zuo X, Chen J, Yang H, Yang Y, Gao Y.

Zhongguo Zhong Yao Za Zhi. 2012 Jan;37(2):125-9. Chinese.

PMID:
22737836

Supplemental Content

Support Center